Tuesday, October 22, 2019
News
NEWS HOME
»
PRESS RELEASES

French Biotech CellVax is Now Able to Propose Preclinical Studies in Large Animals
  SocialTwist Tell-a-Friend  
   


Date: 17-04-2019 11:27AM
Source: CellVax
Category: General, Science & Research, Healthcare & Biotechnology, Medical Devices, Pharmaceutical
Location: Maison-Alfort, France

Business Wire India

  • CellVax announces it has signed strategic partnership with 2 large Chinese pharmaceutical companies: Medtech OSMUNDA, a worldwide leading clinical trial CRO and service provider of medical devices, and big pharmaceutical actor: Guangzhou General Pharmaceutical Research Institute.
  • CellVax is now able to propose to its European customers new standards for preclinical and clinical studies, with large nonrodent animals models
  • Qualifying strategy to meet international standards of scientific quality control
  • Public & private financing underway to support CellVax’s strong growth.

Thanks to this strategic partnership, CellVax can now respond to the strong demand for optimal selection of models that represent the human disease best and is ableto offer preclinical studies in large nonrodent species as well as diversified preclinical models or clinical trials.
Large animal models are essential for the development of novel therapeutics for Cancer and Osteoarthritis (OA) fields, the two research specialties of CellVax. Through this partnership, the company has achieved a significant progress in its capacity to provide wide range of animal models for these diseases.
From now on, CellVax offers to fully realize high value-added projects in China and France / Europe, including product registrations in China for European clients, or a better understanding of European markets for Chinese clients.

Quicker funding to support the growth and to finance quality and R&D resources, innovation driver for CellVax
Since February 2019, CellVax has made a strong commitment to enhance the quality of its preclinical studies. Currently, one large GLP toxicology and Bio-distribution study is ongoing at CellVax.
By the end of 2019, CellVax will be able to perform a full range of GLP-compliant preclinical studies in large and small animals for the development of drugs, vaccines and medical devices.

Furthermore, CellVax is fully invested in numerous large-scale European collaborative research programs such as Eureka, FP-7, and Horizon 2020, as well as in the search for new ways of private / public financing in order to continually enhance its R&D capability and to increase its visibility worldwide.

About CellVax – www.cellvax-pharma.com
Founded in 2001, Cellvax is a preclinical Contract Research Organization (CRO) which provides innovating drug validation studies both in vitro and in vivo allowing to accelerate the drug development process for unmet needs related to severe human diseases, mainly in Cancer and Osteoarthritis fields. In addition to preclinical studies, CellVax provides high quality consulting services in order to optimize the discovery process of candidate compounds.



CONTACTS :

CELLVAX
Dr. Mingxing WEI, CEO
+33 (0) 671434751 (France) +86 182 271 08395 (China)
contact@cellvax-pharma.com

FIN’EXTENSO
Press Relations
Isabelle Aprile
+33 1 39 97 61 22
i.aprile@finextenso.fr

More Press Releases

AROMA BIT Secures 350mn JPY in Series A Funding from Japan Tobacco and East Ventures

Alibaba Kicks Off 2019 11.11 Global Shopping Festival

Delhi’s Vivaan Gupta Becomes the Youngest Indian to Travel All Continents of the World

Growing Sustainability Concerns Will Shape the Indian Soft Drinks Industry

Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNFa Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohn’s Disease

ADX Group Announces IPO Progress, New Cyber Security Offerings

Delta Launches Its Latest Power Quality Solutions and 4K Laser DLP® Video Wall for Railway Transportation at IREE 2019

Kartik Mohindra Now a Part of Keepers of the Quaich, a Global Celebration of Scotch Whisky

Topcoder On-Demand Digital Talent Platform Includes New Data Science, AI Features to Advance Enterprise Analytics

Marconi Society's Celestini Program Recognizes Indian Students Tackling Women's Safety & Air Pollution

Market Leading Manufacturing Companies in India Recognized for Their Global Competitiveness

Winners of “Merck More Than a Mother” Fashion Awards - Zambia Announced by Merck Foundation With the Aim to Break the Stigma Around Infertile Women

Raysut Cement Subsidiary, Pioneer Cement, to Develop USD200 Million Georgia Cement Project

Sparkling Diwali Offers: #JustEMI Your Purchases With Bajaj Finserv During Flipkart’s Big Diwali Sale

New Research Reveals Updated Patient Preferences on Digital Health Technology

The Federal Councilor, Simonetta Sommaruga of Switzerland, Department of Environment, Transport, Energy and Communications, Visits the ABB Ability Innovation Center in Bengaluru

RIMES Opens New Operational Hub in Manila

Bina Modi Conferred With Ph.D., Honoris Causa by Dr. K.N. Modi University

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Exit polls are showing clear victory for...
Delhi: Auto driver held for cheating US ...
PMC Bank scam: Depositors stage protest ...
Will demand death sentence for killers o...
Delhi HC issues notice to EC, Centre on ...
Nothing unconstitutional about dividing ...
More...    
 
 Top Stories
11-yr-old gets evicted from chess t... 
Sensex down 135 pts, Nifty IT index... 
Who is Bezos? Asks US student as Am... 
Infosys shares plunge 15% on whistl... 
Infosys must act with urgency: Expe... 
Not just 1 or 2, every player chipp... 
This Indian team under Virat is tou... 
SC grants bail to Chidambaram in IN...